Xcout Intel
Cloudbreak Pharma competitors & alternatives
The 12 closest competitors and alternatives to Cloudbreak Pharma among pharmaceuticals companies — ranked by similarity to what Cloudbreak Pharma actually does, not by market-cap band.
Subscribe to see Cloudbreak Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Cloudbreak Pharma
Cloudbreak Pharma is an innovative biotechnology company headquartered in Irvine, California, with operations in Hong Kong. The company focuses on ophthalmic drug development, utilizing a robust research and development engine to create novel therapeutic solutions.
Cloudbreak Pharma at a glance
Cloudbreak Pharma is a pharmaceuticals company headquartered in United States. Its most recent funding round raised $15M in July 2026. Xcout tracks 7 named people at Cloudbreak Pharma, including Van Dinh (Chief Operating Officer).
Cloudbreak Pharma leadership
- Van DinhChief Operating Officer
- Abu AbrahamChief Medical Officer
- Elizabeth CapanChief Patent Officer
- Greg BrooksChief Commercial Officer
- Michael RoweChief Business Officer
- Rong YangChief Scientific Officer
1 more named person on record for Cloudbreak Pharma, with roles, board committees and tenure — see the full roster →
Cloudbreak Pharma funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $15M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Cloudbreak Pharma competitors
Ranked by semantic similarity — how close each company is to Cloudbreak Pharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Similar pharmaceuticals company
iRenix Medical is a private company founded in 2016 and headquartered in Palo Alto, California. The firm is engaged in the development of ophthalmic devices and drug pipelines.
Similar pharmaceuticals company
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Hod Hasharon, Israel. The company focuses on the development and commercialization of treatments for ophthalmic and other serious medical conditions.
Biotechnology & Pharmaceuticals
Okogen, Inc. is a biotechnology research company headquartered in Plano, Texas, specializing in innovative eyecare solutions.
Similar pharmaceuticals company
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Similar pharmaceuticals company
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Similar pharmaceuticals company
Harrow Health, Inc. is a specialty pharmaceutical company focused on ophthalmic products, including FDA-approved and compounded medications used in eye care. It serves ophthalmologists, other eye-care professionals, and patients requiring treatments for conditions and procedures involving the eye.
Similar pharmaceuticals company
Laboratoires Théa is a global pharmaceutical company based in France that specializes in ophthalmology and eye care products. Operating through multiple international affiliates and subsidiaries, the company develops and supplies prescription medicines and healthcare solutions to treat various eye diseases.
Similar pharmaceuticals company
Santen Pharmaceutical Co., Ltd. is headquartered in Osaka, Japan, and is a global leader in ophthalmological research, development, production, and marketing of related pharmaceuticals and medical devices.
Similar pharmaceuticals company
Sun Pharma Advanced Research Company Limited (SPARC), a biopharmaceutical firm established in Mumbai, India, in 2006 and operating as a subsidiary of Shanghvi Finance Private Limited, is globally committed to the discovery and advancement of innovative pharmaceutical products. The company's strategic focus involves developing novel chemical and biological entities, as well as improving existing formulations, with a key therapeutic emphasis on conditions within oncology, neurodegeneration, ophthalmology, and dermatology. SPARC currently commercializes Elepsia, a specialized levetiracetam formulation for managing epilepsy, and Xelpros, a latanoprost ophthalmic emulsion prescribed for the treatment of open-angle glaucoma or ocular hypertension. Its robust development pipeline showcases numerous candidates in various clinical trial stages: SDN-037, a difluprednate formulation in Phase 3 for addressing inflammation and pain linked to ocular surgery; PDP-716, also in Phase 3 for glaucoma; and phenobarbital sodium, targeting neonatal seizures. Additionally, the company is progressing Vodobatinib (SCO-088), which has concluded Part A of its Phase 1 study for resistant chronic myelogenous leukemia, and Vodobatinib (SCC-138), currently in Phase 2 for Parkinson's disease. Other pipeline assets include SCD-044, a Phase 2 candidate for psoriasis and atopic dermatitis, and SCO-120, advancing through Phase 1 for hormone receptor-positive, HER2-negative, metastatic breast cancer. Complementing its internal efforts, SPARC engages in strategic collaborations, including one with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders, and another with HitGen Ltd. aimed at identifying promising small molecule leads for selected therapeutic targets.
Similar pharmaceuticals company
Otologic Pharmaceutics is a development-stage biopharmaceutical company headquartered in Oklahoma City, Oklahoma. The company is committed to developing and commercializing novel therapeutics focused on restoring hearing.
Similar pharmaceuticals company
Hudson Pharma is a branded generic pharmaceutical company that develops and manufactures treatments across segments such as respiratory, injectables, ophthalmic, and dermatology. The company serves doctors and patients globally by providing affordable, first-line therapies for conditions ranging from asthma and glaucoma to infections and vitamin deficiencies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Cloudbreak Pharma and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Cloudbreak Pharmaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →